Compounds > carbamates
Page last updated: 2024-10-16

carbamates and Chemotherapy-Induced Acral Erythema

carbamates has been researched along with Chemotherapy-Induced Acral Erythema in 1 studies

Research Excerpts

ExcerptRelevanceReference
"B-rapidly accelerated fibrosarcoma (BRAF) inhibitor encorafenib alone and in combination with MEK inhibitor binimetinib improves survival in BRAF-mutated melanoma patients."7.91The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. ( Barysch, M; Cheng, PF; Conrad, S; Dummer, R; Galliker, N; Goldinger, SM; Graf, NP; Koelblinger, P; Mangana, J, 2019)
"B-rapidly accelerated fibrosarcoma (BRAF) inhibitor encorafenib alone and in combination with MEK inhibitor binimetinib improves survival in BRAF-mutated melanoma patients."3.91The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. ( Barysch, M; Cheng, PF; Conrad, S; Dummer, R; Galliker, N; Goldinger, SM; Graf, NP; Koelblinger, P; Mangana, J, 2019)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Graf, NP1
Koelblinger, P1
Galliker, N1
Conrad, S1
Barysch, M1
Mangana, J1
Dummer, R1
Cheng, PF1
Goldinger, SM1

Other Studies

1 other study available for carbamates and Chemotherapy-Induced Acral Erythema

ArticleYear
The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:4

    Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Drug Eru

2019